FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...

The Food and Drug Administration (FDA) recently approved a first-of-its-kind medication for treating Parkinson’s disease. Patients take JUVMO daily, a prescription medication that mimics the effects ...

Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...

The FDA has approved AbbVie’s once-daily Parkinson’s pill Juvmo, but what does the new treatment mean for patients? Here’s ...

Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

Cambridge, MA USA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned independeltly operated subsidiary of Bayer AG, today announced ...

Deep brain stimulation, a process in which electrodes stimulate specific brain circuits to reduce motor symptoms, has long helped people with Parkinson’s disease manage their tremors — but a new ...

Some 25 years ago, a young Parkinson's disease investigator, Robert Hauser, MD, stepped to the podium at an American Academy of Neurology Conference to present findings from his patient survey that ...

Researchers at UC San Francisco have developed a new way to improve walking for patients with Parkinson's disease using deep brain stimulation and artificial intelligence. Deep brain stimulation (DBS) ...

A small study found disease-related odor compounds may show up in skin samples, including from the navel, but much larger trials are needed.

A Lynnwood man battling Parkinson's disease says his life just got a lot harder after thieves stole the electric bike he ...